Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1997115 | Molecular Cell | 2010 | 8 Pages |
SummaryTumor progression shares many characteristics with the process of epithelial-to-mesenchymal transition (EMT). Cells that have undergone an EMT are known to have an increased resistance to apoptosis. CD95/Fas is an apoptosis-inducing receptor expressed on many tissues and tumor cells. During tumor progression CD95 is frequently downregulated, and tumor cells lose apoptosis sensitivity. miR-200 microRNAs repress both the EMT-inducing ZEB1 and ZEB2 transcription factors. We now demonstrate that miR-200c sensitizes cells to apoptosis mediated by CD95. We have identified the apoptosis inhibitor FAP-1 as a target for miR-200c. FAP-1 was demonstrated to be responsible for the reduced sensitivity to CD95-mediated apoptosis in cells with inhibited miR-200. The identification of FAP-1 as an miR-200c target provides a molecular mechanism to explain both the downregulation of CD95 expression and the reduction in sensitivity of cells to CD95-mediated apoptosis that is observed in the context of reduced miR-200 expression during tumor progression.
► Exogenous miR-200 sensitizes cancer cells to CD95-mediated apoptosis ► miR-200 targets the apoptosis inhibitor FAP-1 ► FAP-1 is a marker for mesenchymal cells ► Regulation of FAP-1 affects the epithelial nature of cancer cells